Every 8-K that BeyondSpring Inc. (BYSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BYSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BYSI filings page.
BeyondSpring Inc. (BYSI) reported that on September 17, 2026 it received a notice from the Nasdaq Listing Qualifications Department that its ordinary shares no longer meet the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
The notice does not immediately delist the shares, and trading on Nasdaq continues. BeyondSpring has 180 calendar days, until March 16, 2027, to regain compliance. Compliance will be restored if the closing bid price is at or above $1.00 for at least 10 consecutive business days. The company may qualify for an additional 180-day period but states there is no assurance it will regain or maintain compliance.
BeyondSpring Inc. reported second-quarter 2026 results and highlighted new clinical data for its lead asset, Plinabulin, in metastatic non-small cell lung cancer (NSCLC). Updated Phase 2 ASCO 2026 data showed a 58.0% two-year overall survival (OS) rate in post–immune checkpoint inhibitor patients, with median progression-free survival of 7.0 months and a generally manageable safety profile. Preclinical AACR 2026 data suggested Plinabulin may enhance the efficacy and tolerability of certain antibody-drug conjugates.
The company is preparing DUBLIN-4, a planned 442-patient confirmatory Phase 3 study of Plinabulin plus docetaxel in non-squamous, EGFR wild-type NSCLC after PD-1/PD-L1 therapy. A leadership transition effective July 1, 2026 installed Min Qiu as Chief Executive Officer, with a mandate focused on advancing DUBLIN-4 and financing activities.
From continuing operations, second-quarter 2026 research and development expenses were $1.0 million, and general and administrative expenses were $0.8 million, leading to a net loss of $1.8 million. For the six months ended June 30, 2026, net loss from continuing operations was $4.1 million. Cash, cash equivalents, and short-term investments totaled $6.5 million as of June 30, 2026, while total liabilities were $50.6 million against total assets of $14.6 million, resulting in a shareholders’ deficit.
BeyondSpring Inc. filed an amended report to detail the finalized employment terms for its new Chief Executive Officer, Min Qiu. His agreement provides a base annual salary of $100,000 and eligibility for a target annual bonus equal to 30% of base salary under the company’s bonus programs.
Qiu will receive options to purchase 100,000 ordinary shares, vesting in four equal annual installments under the 2017 Omnibus Incentive Plan. If he is terminated without cause or resigns for good reason, he is entitled to nine months of continued base salary and a pro-rated annual bonus, plus accelerated vesting of unvested options upon certain change-in-control scenarios. Compensation for CFO Na Li remains unchanged.
BeyondSpring Inc. announced a leadership transition centered on advancing its DUBLIN-4 confirmatory Phase 3 trial of Plinabulin for non-small cell lung cancer. Founder and CEO Dr. Lan Huang will step down as Chief Executive Officer effective July 1, 2026, remaining as Chair of the Board while dedicating her operational focus to SEED Therapeutics.
Min Qiu will become Chief Executive Officer and Na Li will become Chief Financial Officer on July 1, 2026, bringing capital markets and cross-border pharma experience. Director Dr. Jiangwen (Jen) Majeti will serve as Vice Chair and receive options to purchase 100,000 ordinary shares, vesting over four years under the 2017 Omnibus Incentive Plan. The company highlights DUBLIN-4, its 442-patient confirmatory Phase 3 study, and prior DUBLIN-3 results showing Plinabulin plus docetaxel doubled two- and three-year survival and reduced grade 4 neutropenia from 33% to 5%, as the strategic focus of the new leadership structure.
BeyondSpring Inc. reported first-quarter 2026 results showing a shift from profit to loss while advancing its oncology pipeline. Net loss was $6.7 million for the quarter ended March 31, 2026, compared with net income of $1.2 million a year earlier, driven mainly by losses in discontinued operations.
From continuing operations, net loss narrowed slightly to $2.4 million from $2.6 million as research and development expenses rose to $1.1 million and general and administrative costs fell to $1.1 million. Cash, cash equivalents, and short-term investments totaled $7.9 million as of March 31, 2026, with shareholders’ deficit at $30.4 million.
Strategically, BeyondSpring highlighted new preclinical data suggesting its lead asset Plinabulin may enhance efficacy and tolerability of antibody-drug conjugate regimens, and announced that SEED Therapeutics advanced RBM39 molecular glue degrader ST-01156 into Phase 1 clinical development using a biomarker-driven approach.
BeyondSpring Inc. reported full-year 2025 results and highlighted major clinical milestones for its lead cancer drug Plinabulin and equity affiliate SEED Therapeutics. For continuing operations, research and development expenses rose to $4.4 million from $2.6 million, while general and administrative expenses decreased to $4.6 million from $6.1 million. Net loss from continuing operations was $8.7 million, similar to $8.9 million in 2024, and cash, cash equivalents and short-term investments totaled $12.6 million as of December 31, 2025. Including discontinued operations related to SEED, net loss was $14.2 million, but net loss attributable to BeyondSpring narrowed sharply to $1.0 million, with basic and diluted loss per share improving to $0.02 from $0.28. Clinically, Phase 3 DUBLIN-3 data in EGFR wild-type NSCLC showed a statistically significant overall survival benefit for Plinabulin plus docetaxel versus docetaxel alone, with a hazard ratio of 0.72 and a 2.5-month median overall survival improvement, and supported plans for the global Phase 3 DUBLIN-4 confirmatory trial. Early combination studies suggested Plinabulin may help overcome resistance to PD-1/PD-L1 therapies. SEED advanced its RBM39 degrader ST‑01156 into Phase 1a trials, secured U.S. Orphan Drug and Rare Pediatric Disease designations, and completed a $30 million Series A‑3 financing.
BeyondSpring Inc. reports an expected delay in completing the “Second Closings” of its sale of Series A-1 Preferred Shares of SEED Therapeutics Inc. under previously signed purchase agreements.
The company had agreed to sell an aggregate 8,333,637 SEED Series A-1 Preferred Shares for approximately $35.4 million, or $4.25 per share. As part of this, Winning View Investment Limited, FULL TECH CORPORATE DEVELOPMENT LIMITED and Mapfil Investment Limited are scheduled to buy 1,436,327, 555,576 and 1,111,152 shares, respectively, in the Second Closings.
These Second Closings were originally to occur no later than December 15, 2025, but are now expected to be completed in the first half of 2026, with no assurance against further delays or certainty on the exact timing.
BeyondSpring Inc. entered into a Securities Purchase Agreement with Ray Beauty Group Limited for a registered offering of 800,000 ordinary shares at $2.50 per share. The transaction closed on November 21, 2025, providing gross proceeds of $2.0 million before expenses. The shares were issued off an effective shelf registration statement on Form S-3. The investor agreed to a 60-day lock-up from closing, limiting sales and derivative transactions in the shares without the company’s prior written consent, subject to specified exceptions.
BeyondSpring Inc. (BYSI) furnished a current report to announce it issued a press release with financial results for the quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 and is incorporated by reference.
The company states the information in this report, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act.
BeyondSpring Inc. reports that its majority-owned indirect subsidiary SEED Therapeutics Inc. has completed a second closing of its Series A-3 financing. On September 22, 2025, SEED entered into share purchase agreements with third-party investors to sell an aggregate of 1,411,761 Series A-3 Preferred Shares for an aggregate cash purchase price of $6 million, at $4.25 per share.
This follows SEED’s August 2024 sale of 5,647,059 Series A-3 Preferred Shares for $24 million at the same price per share. After the second close, BeyondSpring and its subsidiary SEED Technology Limited are expected to own approximately 38.03% of SEED’s outstanding equity on an as-converted basis, excluding any employee equity plans. BeyondSpring expects that SEED will continue to be consolidated into its financial statements because BeyondSpring believes it remains in substantive control of SEED.
BeyondSpring Inc. held its 2025 annual meeting of shareholders on September 15, 2025. Shareholders representing 21,852,265 ordinary shares, or approximately 54.19% of the 40,322,320 outstanding shares entitled to vote as of the July 25, 2025 record date, were present or represented by proxy. Shareholders ratified the appointment of CBIZ CPAs P.C. as the companys independent registered public accounting firm for the fiscal year ending December 31, 2025, with 21,831,390 votes in favor, 14,265 against, and 6,610 abstentions.
BeyondSpring Inc. filed a current report to note that it released a press release with its financial results for the quarter ended June 30, 2025. The company furnished this press release as an exhibit, meaning it is made available for investors’ information but is not treated as part of the company’s formally "filed" financial statements under securities laws. The filing also confirms that BeyondSpring’s ordinary shares continue to trade on The NASDAQ Stock Market under the symbol BYSI.